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Abstract
Background: Chronic Hepatitis B infection is a major health problem in Republic of Congo therefore molecular
analysis of HBV strains is important to detect the patients at high risk of disease progression.
Methods: Serum samples were obtained from 111 chronic HBV patients in Pointe Noire. HBsAg, HBeAg and HBeAb
were detected. A fragment of the preS1 region of HBV was amplified and sequenced to determine genotypes,
subgenotypes and to identify mutations.
Results: Of the 111 samples analyzed, 35 patients were asymptomatic carriers (ASC), 24 with a chronic active
hepatitis (CAH), 33 with liver cirrhosis (LC) and 19 have a hepatocellular carcinoma (HCC). The mean age were 45 ±
13 year, 88 (79.3 %) were male and 23 (20.7 %) female. The prevalence of HBeAg was 15.3 % and 73 % of subjects
were anti-HBe positive. The mean serum level of alanine aminotransferase transaminase (ALT) and aspartate
transaminase (AST) was 25.1 ± 9 IU/L and 28.6 ± 10 IU/L respectively. Eighty two samples out of 111 (73.9 %) were
genotyped by the analyzing of the S region of HBV, 58 (70.7 %) cases belonged to HBV genotype E and 24 (29.3 %)
were genotype A with three subgenotypes; A3 (66.7 %), A4 (20.8 %) and A6 (12.5 %). Prevalence of genotype A was
relatively high in CAH (33.3 %) and HCC (31.6 %) patients in comparison with other groups. The most prevalent
amino acids substitutions were R38K found in 14 (17.1 %) sequences, following by H44L in 11 (13.4 %), K13E in 8 (9.
8 %), N29K in 8 (9.8 %), A35E in 8 (9.8 %), V80I in 7 (8.5 %) and in 6 (7.3 %) sequences for S90T. Different
substitutions located in the hepatocyte binding site were higher among patients with LC and HCC (p < 0.05).
Conclusions: This study have shown that HBV genotype E and A were the most frequent strains circulating in
Republic of Congo patients. HBV pres1 substitutions found in this study were associated with severe clinical forms
of liver diseases. This data have shown the importance of implementing an effective program to fight HBV
infection.
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Background
Hepatitis B virus (HBV) infection varies from an acute and
chronic phase liver diseases with progression to cirrhosis
and hepatocellular carcinoma (HCC) [1]. HBV is a serious
public health problem, nearly two billion people worldwide
were infected and more than 350 million people live with
chronic infection [2]. HBV is a partially double-stranded
circular DNA virus and has high genetic variability. Cur-
rently, there are ten genotypes designated A to J, based on
an intra-group nucleotide divergence of up to 4.2 % of the
S-genome sequences or in >8 % of the entire genome se-
quences [3]. These genotypes have a specific geographic
distribution worldwide [4]. HBV genotypes A and D have
global distributions, genotypes B and C are endemic in
Asia; genotype E originates from West and sub-Saharan
Africa, genotypes F and H are restricted in Central and
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South America, genotype G has been reported in Europe
and North America; two new genotypes I and J, identified
respectively in South-East Asia and Japan [5–8]. In Africa
area, the management of chronic hepatitis B is a major
health problem, due to the late detection of infection and
lack of effective monitoring means [5]. HBV contains a
polymerase enzyme without proofreading activity, high
error frequencies on RNA or DNA copying are selected
during replication phase, resulting in mutations that play a
substantial role in determination of the clinical pathogen-
esis degree [9, 10]. Recently, several studies have reported
the presence of mutations in pre-S, basal core promoter
(BCP) and the precore (PC) regions are highly correlated
with the severity of HBV-related liver diseases, including fi-
brosis, cirrhosis and HCC [11–13]. Moreover, several
mechanisms are reported to be associated with fulminate
hepatitis B which includes specifically mutations in the
major hydrophilic loop or in the “a” determinant region of
S gene [14, 15]. Many studies reported that Pre-S mutants
lead accumulation of large envelope proteins in the endo-
plasmic reticulum (ER), resulting in ER stress associated
with aggravated liver disease [16, 17]. Republic of Congo is
classified as having high endemicity of HBV [18] with a
prevalence of Hepatitis B surface antigen (HBsAg) ranges
from 6.5 % to 11.4 % [19–22]. The average length of sur-
vival is low due to stage of gravity and to late hospitalization
of patients [23]. This virus is considered as the most com-
mon cause of cirrhosis (63 %) and HCC (73.5 %) in Pointe
Noire and Brazzaville [24, 25]. Despite all this data, none
molecular study have been performed in Republic of
Congo. Thus, this first work aimed to characterize the dif-
ferent strains of HBV in chronic carriers; it might constitute
an effective basis to fight against this infection.
Methods
Patients and serum samples
This is a cohort study, conducted in chronic HBV patients
followed in the pathology department at the hospital
Adolphe Sice in Pointe Noire, during the period from
February to September 2014. Serum samples were obtained
from 111 patients with chronic HBV infection and all pa-
tients were known to have been positive for HBsAg during
the previous 6 months. The demographic data including
gender, age and biochemical data such as alanine amino-
transferase transaminase (ALT) and aspartate transaminase
(AST) levels were also available for these patients. Four
groups of patients were classified according to their clinical
diagnosis based on liver biochemical tests, hepatitis virus
markers, alfa-fetoprotein (AFP) and ultrasonography, it
consists in: 35 patients with asymptomatic carriers (ASC),
24 patients with chronic active hepatitis (CAH), 33 with
liver cirrhosis (LC) and 19 patients with HCC. Five milliliter
of blood was collected from each participant and the serum
was separated and stored at -70 °C until used.
Informed consent was obtained from all participating
subjects. The study protocol conformed to the Declar-
ation of Helsinki, and was approved by the Ethics Com-
mittee of Research in Health Sciences in Republic of
Congo.
Serologic test for HBV markers
All serum samples were tested for HBsAg (Monolisa™
HBsAg ULTRA), hepatitis B e antigen (HBeAg) and
hepatitis B e antibody (Monolisa™ HBe Ag-Ab PLUS)
using an enzyme linked immunosorbent assay (ELISA)
according to the manufacturer’s instructions (Monolisa,
Bio-Rad Laboratories, Marnes La Coquette).
DNA Extraction
We used a standard method of phenol/chloroform to ex-
tract DNA [26], 400 μl of serum was mixed with 300 μl
of lysis buffer (1 M Tris-HCl, pH 8.0, 0.2 M EDTA, 5 %
SDS and 5 M NaCl) in the presence of 5 μl of 20 mg/ml
proteinase K (Promega Corp., WI, USA) and incubated
at 56 °C for 2 h. Then DNA was precipitated with 2/5
volumes of 7.4 M ammonium acetate and 2 volumes of
96 % ethanol. The DNA was resuspended in RNase free
water and stored at –20 °C until use.
HBV DNA amplification and sequencing of the preS1
region
Detection of HBV DNA was performed by a nested PCR
and amplifying of the fragments covering the preS1 gene of
HBV with two consensus primers. The sequence of the
PCR primers were HBPr1 (nt 2850–2868,5’-GGGTCACCA
TATTCTTGGG-3’) and HBPr135 (nt803-822, 5’- CAAGA
CAAAAGAAAATTGG-3’) for the outer primer pair and
HBPr2 (nt 2867–2888, 5’-GAACAAGAGCTACAGCAT
GGG-3’) and HBPr3 (nt 1547–1569, 5’- CCACTGCATGG
CCTGAGGATG-3’) for the inner one, as previously de-
scribed by Stuyver et al. [7]. Briefly, the first round PCR
was performed in a 20 μl mixture containing 5 μl DNA,
10 mM of dNTPs, 2.5 mM of MgCl2, 1X colorless GoTaq®
Flexi Buffer and 10 mM of each primer, 0.2 U of GoTaq®
DNA Polymerase (Promega, Madinson, USA). For the sec-
ond round PCR, 2 μl of the first round PCR product was
used as DNA template. For the both the first and second
round, the thermocycling profile consisted of AmpliTaq ac-
tivation at 94 °C for 5 min, followed by 35 cycles of PCR
amplification using the following temperatures: denatur-
ation at 94 °C for 30 s, annealing at 50 °C for 30 s and ex-
tension at 72 °C for 30 s, with a final elongation at 72 °C for
7 min. All PCR amplification were performed in a Perkin
Elmer 2400 GeneAmpR® PCR thermal Cycler (Scientific
Support, Inc, Hayward, CA). The products were analyzed
on a 2 % agarose gel and visualized by staining with eth-
idium bromide.
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Phylogenetic analysis
HBV genotypes were determined using phylogenetic ana-
lysis. All HBV sequences were aligned with corresponding
sequences of HBV belonging to genotype A-J obtained
from GenBank database (http://www.ncbi.nih.gov). Mul-
tiple sequence alignment was edited by Bioedit software
[27] and subsequently manually edited to remove gaps or
ambiguously aligned sites. The phylogenetic tree was con-
structed using the neighbor-joining method by MEGA
software version 6.0.5 [28] and the reliability of the tree
was evaluated by means of bootstrap analysis with 1000
replicates. Pairwise evolutionary distances were computed
using the Kimura two parameter model.
Nucleotide sequence accession numbers
The nucleotide sequence data reported in this paper
have been submitted to the GenBank databases under
accession numbers KX130002 - KX130083.
Statistical analysis
Statistical tests were performed using EpiInfo software
version 7.0 (Centers for Disease Control and Prevention
and World Health Organization, Geneva, Switzerland).
Data were expressed as mean ± SD and percentages.
Comparisons between groups were analyzed by chi-
square test and p-value of less than 0.05 was considered
statistically significant.
Results
In overall, 111 chronic patients were enrolled in this study.
The mean age of patients was 45 ± 13 (range, 21 to 68)
year, of that, 88 (79.3 %) patients were male and 23
(20.7 %) female. The prevalence of HBeAg was 15.3 % and
73 % of subjects were anti-HBe positive. The presence of
HBeAg was high in CAH (41.18 %) and HBeAb positive
was higher in the age group 39-45 year with a prevalence
of 56.7 %. The mean serum level of ALT and AST was
25.1 ± 9 IU/L and 28.6 ± 10 IU/L respectively. The ALT
and AST was significantly different among CAH and
other clinical status (Table 1). However, no correlation
was found in the transaminases levels regarding the HBe
status and clinical diagnosis (P > 0.05).
Eighty two samples out of 111 (73.9 %) were genotyped
in the HBV S region. HBV DNA was detected in 68.6 %
(24/35) of ASC, 79.2 % (19/24) of CAH, 76.8 % (25/33) of
LC and 73.7 % (14/19) of HCC. Of these, 58 (70.7 %) sub-
jects were infected with HBV genotype E and 24 (29.3 %)
were infected with HBV genotype A. The subgenotypes of
these 24 HBV/A isolates were further determined by com-
parison with references sequences, 16 strains belonged to
subgenotypes A3 (66.7 %), 5 to A4 (20.8 %) and 3 were
subtype A6 (12.5 %) (Fig. 1). The Association between
liver disease and the prevalence of HBV genotypes have
shown that, an overall predominance of HBV genotype E.
HBV genotype A was higher in CAH (33.3 %) and HCC
(31.6 %) patients. There was no significant difference be-
tween age and biochemical parameters of liver disease ac-
cording to different genotypes (p > 0.05).
Frequency and distribution of mutations in the preS1
region
Among the 82 (73.9 %) strains sequenced in pres1 re-
gion, different amino acid substitutions were detected
(Fig. 2). The most prevalent variant were R38K found in
14 (17.1 %) sequences, following by H44L in 11 (13.4 %),
K13E in 8 (9.8 %), N29K in 8 (9.8 %), A35E in 8 (9.8 %),
V80I in 7 (8.5 %) and in 6 (7.3 %) sequences for S90T
(Table 2).
The distribution of substitutions in pres1 region, shown
8.5 % (7/82) of mutations observed were located in B-cell
and T-cell region and in hepatocyte binding site including
R38K (17.1 %), H44L (13.4 %) and N29K (9.8 %). In
addition, some other mutations were observed in the S pro-
moter region and CCAAT box including V80I in 7 (8.5 %)
cases and S90T in 6 (7.3 %) strains. These mutations were
observed among different clinical groups; In the 11 se-
quences with R38K (17.1 %, 14/82) substitutions, high rate
were observed in patients with LC (35.7 %, 5/14) and HCC
(28.6 %, 4/14). The sequences with A35E and H44L amino
acid substitutions were significantly more frequent in cases
with LCC and HCC infection than in other patients groups
(P < 0.05). There was no significant difference between
substitutions V80I and S90T found in S promoter region
with clinical status. Regarding preS1 mutations, these
Table 1 Distribution of demographic and clinical characteristics
of chronic hepatitis B patients in Pointe Noire, Republic of
Congo (2014)
Characteristics Clinical Status
ASC (35) CAH (24) LC (33) HCC (19)
Gender
Male n(%) 28 (80) 19(79.2) 27 (81.8) 14(73.7)
Female n(%) 7 (30) 5 (20.8) 6(18.2) 5 (26.3)
Age (%)
21-39 11 (31.4) 13 (54.2)a 8 (24.2) 3 (15.8)
40-55 20 (57.1)a 5 (20.8) 15 (45.5) 7 (36.8)
56-68 4 (11.4) 6 (25) 10 (30.3) 9 (47.4)
ALT (IU/l), mean ± SD 15.8 ± 3 34.4 ± 6 25.6 ± 7 29.4 ± 5
AST (IU/l), mean ± SD 20.8 ± 7 42.1 ± 8 28.3 ± 6 26.5 ± 4
HBeAg positive(%) 2 (5.7) 7 (29.2)a 5 (15.2) 3 (15.8)
HBeAb positive(%) 28 (80) 14 (58.3) 24 (72.7) 15 (78.9)
HBV genotype(%)
HBV/A 6 (17.1) 8 (33.3) 4 (12.1) 6 (31.6)
HBV/E 18 ((51.4) 11 (45.8) 21 (63.6) 8 (42.1)
ASC asymptomatic carriers, CAH chronic active hepatitis, LC liver cirrhosis, HCC
hepatocellular carcinoma (HCC), a significant difference
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substitutions were low in ASC patients in comparison
with LC and HCC subjects (p > 0.05). Furthermore, nearly
63 % of the HBV pre-S mutants were observed in patients
over 40 years age, but no considerable difference was found
in patients less than 39 years of age (p > 0.05) (Table 1).
Discussion
Hepatitis B infection is hyperendemic in Republic of
Congo and determination of genetic diversity has a vital
interest in the characterization of the virus, liver dam-
age, reaction to antiviral and evolution of infection.
In this present study, a relative young age (<30 years)
of HBeAg carriers were observed. This finding is in
agreement with other studies in Africa which indicate
that perinatal transmission still persists with a significant
risk of chronicity [29]. HBV DNA was found in 73.9 %
of HBsAg patients, all these subjects were HBeAg posi-
tive and HBeAb was present in 58.6 % of samples. In-
deed, some studies have reported that active HBV
replication and a high ALT level may persist in patients
with chronic HBV after HBeAg seroconversion [30]. Fur-
thermore, chronic HBV patients with HBeAg negative
have a risk of develop a severe form of liver disease that
often progresses to cirrhosis and HCC [31].
The determination of HBV genotypes were based
on amplification of the HBV S region, it has shown
two main genotypes, HBV E (70.7 %) and A (29.3 %).
This finding is in agreement with previous studies,
which have reported that the genotype E is predom-
inant in Africa and has rarely been found in other
continents, except for a few cases mostly in individ-
uals with an African background [6, 32–34]. HBV
genotype A is found mainly in Northern and West-
ern Europe, North America and Africa [5]. This
genotype is subdivided into seven subgenotypes (A1
to A7) [35]. In this present study, we found the sub-
genotypes A3 (66.7 %), A4 (20.8 %) and A6 (12.5 %).
The recent work carried out by Kurbanov et al., has
detected the genotype A3 in Central and West Africa
[36]. Some subgenotypes have been found in other
countries; A4 was reported in Gambia and subgeno-
type A5 was reported in Nigeria and among African
descendants in Haiti [37, 38]. Study conducted by
Pourkarim et al., has found A6 strains from African-
Belgian patients while A7 subtype was found by
Hübschen et al in Rwanda and Cameroon [39, 40].
The low frequency of HBeAg positivity in both geno-
types E and A found in this study, was reported in other
Fig. 1 Phylogenetic analysis was based on nucleotide sequencing on the preS1 region of HBV. The sequences of the Congolese patients were
compared with representative sequences of all HBV genotypes and subgenotypes (A to I) retrieved from GenBank database. The sequences are
labeled by their accession numbers and country, [CAR, Central African Republic; DRC, Democratic Republic of Congo]. The phylogenetic tree was
generated by MEGA 6.0 program using the neighbor-joining method and bootstrap values were obtained from 1000 replicates
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Fig. 2 Alignments of deduced amino acid sequences of pre-S1 from OBI strains compared to the consensus sequence of genotype E (AB091255)
and genotype A (AM184126) retrieved from GenBank database. The amino acids were identified by single letter code. Dots represent identical
amino acids with the reference consensus sequences for genotype E or A shown on top of each sequence. The immune epitopes corresponding
to B-and T-cell (aa12-53), hepatocyte binding site (aa 21-47), S promoter (nt 3045-3180) and CCAAT box (nt 3137-3141) are marked correspondingly at
the top of the alignment. aa, amino acid; nt, nucleotide
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studies in Africa [34, 41]. The study performed by Brichler
et al., in Martinique, have reported that patients infected
with HBV/A1 strains were more often HBeAg negative
than those infected with genotype A2 or D [8]. In the
other hand, Livingston et al., in Alaska have shown that
the average age of HBeAg seroconversion to anti-HBe is
lower in patients infected with genotypes A, B, D and F, as
compared with genotype C [42]. Furthermore, it has re-
ported that the anti-HBe seroconversion period is related
to HBV genotypes; for genotype D, the median time was
less than six years with a rapid evolution into HBe Ag
negative mutant forms [29, 42].
In this study, HBV genotype E was predominant in all
patient groups and HBV/A was relatively higher in CAH
(33.3 %) and HCC (31.6 %) patients. Several studies
performed in China, have shown a predominance of HBV
genotypes C and B in patients with chronic liver disease,
followed by genotypes D, E and A [43, 44]. The study car-
ried in Indian subcontinent, demonstrated that the HBV
genotypes D and F were associated with the genesis of
HCC with a high morbidity [45]. Indeed, structural and
functional differences between genotypes can influence the
severity, complications and hepatitis B e antigen (HBeAg)
seroconversion. HBV genotype E is described as being less
linked to serious clinical manifestations than other geno-
types with lower HBeAg positivity [34].
The phylogenetic analysis based on the sequencing of
the HBV preS1 region have reported many substitutions;
the most prevalent variant found were R38K in
14(17.1 %) sequences, following by H44L in 11(13.4 %)
and K13E in 8(9.8 %) strains. Similar studies carried out
in endemic countries, reported a HBV preS mutant
prevalence have ranged from 0 % to 36 % in chronics
HBV patients [9, 17, 46]. Our data show a significant
high frequency of preS1 mutants in the LC and HCC
subjects (P < 0.05). Indeed, several studies suggest that
HBV preS mutations were associated with cirrhosis and
the development of HCC [14, 47, 48].
In this work, 8.5 % of sequences have substitutions in
the start codons, which can disrupt the synthesis of vi-
rions and impact HBV life cycle [49]. The major muta-
tion found in epitope B-cell and T-cell and hepatocyte
binding site were R38K (17.1 %), H44L (13.4 %) and
N29K in 8 (9.8 %) sequences. This region plays an essen-
tial role in viral clearance and clinical recovery during
natural infection [49]. Therefore, these mutations are de-
terminant of viral persistence and may contribute fur-
ther to the persistence of infection [50]. In the other
hand, the main substitutions observed in the S promoter
region and CCAAT box were V80I in 7(8.5 %) and S90T
in 6(7.3 %) of sequences. A recent study performed by
Yeung et al., has found deletion in S promoter region
and CCAAT box in 38.1 % of cases and 16.7 %, respect-
ively [14]. Another study performed by Sugauchi et al.,
detected the preS deletion mutants in 34 % patients with
advanced liver disease and only 8 % of patients with clin-
ical disease had a defect in the CCAAT box in the S pro-
moter region [11].
Our study found no difference of mutation distribution
according to HBe status; this is in agreement with the re-
sults from Pollicino et al., demonstrating that the emer-
gence of preS/S mutants was comparable between HBeAg
positive and HBeAg-negative patients [51]. We also found
that preS mutations were more frequent in carriers of HBV
genotype E than in those of genotype A. Indeed, mutations
and evolution of HBV infection are different depending on
genotypes and geographic location [11, 52]. A study per-
formed in India, found a high prevalence of preS mutations
among HBV carriers with genotype C (38.89 %) followed by
HBV/A (33.33 %) and HBV/D (22.50 %) [17]. Furthermore,
the studies carried in China among HBV carriers with pro-
gressive liver diseases, showed that preS deletion was more
frequent in carriers of HBV genotype C than in those of
genotype B [11, 50].
The high incidence of HBV preS1 mutations were
found in LC (28.7 %) and HCC (41.6 %) patients group,
followed by ASC (13.3 %) and ACH (16.4 %). In a
Table 2 Distribution of the PreS1 mutation prevalent among
chronic hepatitis B patients according to clinical status
Amino acid
substitutions
Number of
isolates(%)
Genotype ASC CAH LC HCC Type of
Epitope
K13E 8 E 0 2 2 4
N14K 5 E 1 2 2 0
H15Y 5 E 1 2 2 0
N19T 5 E 0 2 1 2 B and T-cell
P25L 6 E 0 1 1 2 &
N29K 8 A 1 2 2 3 Hepatocyte-
binding site
P30Q 7 A 2 2 2 3
A35E 8 E 0 0 5 3
R38K 14 E 2 3 5 4
R38G 4 E 1 0 1 2
W42G 4 E 0 1 0 3
H44L 11 E 2 1 4 4
V49A 6 A 0 3 1 2
T52R 5 E 1 1 1 2
P64S 4 E 1 1 2 0 S promoter
(nt 3019-3201)
V80I 7 A 2 0 2 3
K85Q 4 E 2 1 1 0
S90T 6 A 1 3 0 2
S100V 4 E 1 1 2 0
ASC asymptomatic carriers, CAH chronic active hepatitis, LC liver cirrhosis, HCC
hepatocellular carcinoma (HCC), nt nucleotide
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previous study performed in China, the preS mutation
rates were relatively low (2 %) in patients with acute
HBV infection and a higher prevalence of preS1 dele-
tions in HCC patients than in those with liver cirrhosis
(43.1 % vs 35.2 %) [16]. In addition, Yeung et al. in Hong
Kong have reported that patients with HCC had a higher
prevalence of HBV with pre-S deletions than did pa-
tients without HCC (23 [33.3 %] of 69 vs 11 [15.9 %] of
69) [14]. The meta-analysis performed by Shijian et al.
found that the PreS mutations were associated with
3.77-fold increased risk of HCC compared with HBV
without mutations [53]. In fact, it has been reported that
the preS mutants are involved in the mechanism of cyto-
plasmic retention of large surface protein. This accumu-
lation can activate cellular grp78 and grp94 promoters
by inducing endoplasmic reticulum stress and lead to
oxidative DNA damage of HBV-infected hepatocytes
[54]. Thus, the presence of oxidative DNA lesions stimu-
lates DNA repair activity and the induced genomic in-
stability may lead to liver damage and HCC [55, 56].
Conclusion
This study shown that HBV genotype E and A were the
most frequent strain circulating in Congolese patients.
HBV genotype E was predominant in all patient groups
and genotype A was significant in LC and HCC patients.
Different HBV pres1 substitutions found in this study were
located in the hepatocyte binding epitope and have possible
association with the development of progressive liver dis-
eases in chronic HBV carriers. These data are of paramount
importance for decision making in relation to the adoption
of treatment strategies and shown the necessity to imple-
ment of an effective program to fight HBV infection.
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